First patient receives Forzinity in Mighty Therapeutics’ Phase IV study

Phase 3ForzinityNeutral

AI Analysis

Summary

Mighty Therapeutics has enrolled the first patient in the 4TAZPower Phase IV confirmatory study evaluating Forzinity injection in patients aged five years or older with Barth syndrome.

Clinical Trial Data

Phase

Phase IV

Importance:4/10

Sentiment:

0.00

Mighty TherapeuticsForzinityBarth syndromePhase IV4TAZPower

Related Companies

$GBCYD $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 9, 2026 9:12 AM

Read Original